Información:
Error:
ID
22005
Descripción
Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00866749
Link
https://clinicaltrials.gov/show/NCT00866749
Palabras clave
Versiones (1)
- 14/5/17 14/5/17 -
Subido en
14 de mayo de 2017
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Lymphoblastic Leukemia NCT00866749
Eligibility Lymphoblastic Leukemia NCT00866749
- StudyEvent: Eligibility
Similar models
Eligibility Lymphoblastic Leukemia NCT00866749
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
lymphoblastic leukemia, lymphoblastic lymphoma
Item
1. patients must have precursor-b or t-lymphoblastic leukemia or lymphoblastic lymphoma.
boolean
C0023448 (UMLS CUI [1])
C0079748 (UMLS CUI [2])
C0079748 (UMLS CUI [2])
prior chemotherapy
Item
2. patients must be untreated or have had only one prior chemotherapy regimen for all or ll . previously treated patients will be analyzed separately.
boolean
C1514457 (UMLS CUI [1])
age
Item
3. age between 12 to 40 years old
boolean
C0001779 (UMLS CUI [1])
cns, testicular disease
Item
4. patients with cns disease or testicular disease are eligible.
boolean
C0007682 (UMLS CUI [1])
C0039584 (UMLS CUI [2])
C0039584 (UMLS CUI [2])
cytarabine intrathecal therapy, systemic chemotherapy
Item
5. intrathecal therapy with cytarabine is allowed prior to registration for patient convenience. this is usually done at the time of the diagnostic bone marrow or venous line placement to avoid a second lumbar puncture. systemic chemotherapy must begin within 72 hours of the first intrathecal treatment.
boolean
C1831734 (UMLS CUI [1,1])
C0010711 (UMLS CUI [1,2])
C1883256 (UMLS CUI [2])
C0010711 (UMLS CUI [1,2])
C1883256 (UMLS CUI [2])
informed consent
Item
6. signed informed consent prior to the start of systemic therapy. in the event of enrollment of a minor patient, an attempt to obtain assent from the patient must be documented, and parental consent must be signed.
boolean
C0021430 (UMLS CUI [1])
ecg, cardiac risk factors
Item
7. echocardiogram should be done within 72 hours of starting therapy if there are cardiac risk factors (e.g., history of hypertension or of myocardial infarction)
boolean
C1623258 (UMLS CUI [1,1])
C2024776 (UMLS CUI [1,2])
C2024776 (UMLS CUI [1,2])
creatinine, bilirubin
Item
8. creatinine should be < 3 mg/dl bilirubin < 3 mg/dl unless felt to be due to disease
boolean
C0201976 (UMLS CUI [1])
C1278039 (UMLS CUI [2])
C1278039 (UMLS CUI [2])
zubrod performance status
Item
9. zubrod performance status of <3
boolean
C3714786 (UMLS CUI [1])
steroids
Item
10. patients who received steroids more than 72 hours prior to study enrollment are eligible but will be analyzed separately
boolean
C0038317 (UMLS CUI [1])
age
Item
1. age less than twelve years of age or greater than 40 years.
boolean
C0001779 (UMLS CUI [1])
prior chemotherapy
Item
2. more than one prior treatment regimen for all or ll.
boolean
C1514457 (UMLS CUI [1])
pregnancy, effective contraception
Item
3. the patient is pregnant or unwilling to practice appropriate birth control.
boolean
C0032961 (UMLS CUI [1])
C0700589 (UMLS CUI [2])
C0700589 (UMLS CUI [2])
philadelphia chromosome
Item
4. presence of the philadelphia chromosome t(9;22)
boolean
C0031526 (UMLS CUI [1])